ArticleThe Journal of antimicrobial chemotherapy2026
Towards standardized antifungal susceptibility testing for Sporothrix brasiliensis.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Sporotrichosis caused by Sporothrix brasiliensis is increasingly reported in South America. Infections in humans are mostly due to zoonotic transmission by cats. For both hosts, itraconazole is the drug of choice despite long treatment duration. Resistance surveillance is warranted, but protocols for antifungal susceptibility testing (AFST) are not always harmonized between laboratories largely due to Sporothrix species being thermally dimorphic and the absence of well-defined consensus methodologies to address how to deal with yeast/mould phases. To standardize susceptibility testing methodology, we propose to modify the current Clinical Laboratory and Standards Institute (CLSI) M38 broth microdilution methodology with S. brasiliensis culture for 7 days at 30°C (rather than 35°C) on potato dextrose agar (PDA), followed by microscopic confirmation of pure mycelial phase. Incubation temperature would also be modified to 30°C for 72 hours. By following this standardized method for at least itraconazole, terbinafine and amphotericin B, S. brasiliensis non-wild-type isolates and correlations with clinical outcomes can be properly investigated. The proposed method is a consensus-oriented interim approach rather than a fully validated standard.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.